23:58 , Jun 5, 2019 |  BC Extra  |  Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
12:40 , Apr 3, 2019 |  BC Extra  |  Company News

Editas, BlueRock to combine technologies for engineered cell medicines

Gene editing company Editas and cell therapy play BlueRock are collaborating to develop engineered, allogeneic cell medicines to treat neurologic, cardiologic, and immunologic disorders and cancer. Under a deal announced Wednesday, the companies will combine...
23:09 , Mar 29, 2019 |  BC Extra  |  Company News

Management tracks: Insmed, AACR, BlueRock

Pulmonary disease company Insmed said Paolo Tombesi will step down as CFO and remain a consultant, effective June 2. Insmed Inc. (NASDAQ:INSM) will begin to search for a successor. It also promoted John Goll to...
00:53 , Feb 1, 2019 |  BC Innovations  |  Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
18:26 , Nov 30, 2018 |  BC Week In Review  |  Company News

Bayer cuts 900 pharma jobs to invest externally

Bayer AG (Xetra:BAYN) plans to increase its investment in external innovations using funds it will save from cutting 900 positions from its pharma division. The company said it will also focus on "collaborative research models."...
00:01 , Nov 30, 2018 |  BC Extra  |  Company News

Bayer cuts 900 pharma jobs to invest externally

Bayer AG (Xetra:BAYN) plans to increase its investment in external innovations using funds it will save from cutting 900 positions from its pharma division. The company said it will also focus on "collaborative research models."...
21:14 , Oct 3, 2018 |  BC Extra  |  Company News

Management tracks: ARM, Rewind, Exscientia

The Alliance for Regenerative Medicine, an advocacy organization for regenerative medicines including cell and gene therapies, appointed Matthew Patterson as chairman for 2019. The group also named Emile Nuwaysir as vice chairman, Amy Butler as...
22:35 , Sep 20, 2018 |  BC Extra  |  Company News

Management tracks: Garland to lead Portola; Gallagher joining Abingworth

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) hired Scott Garland as president and CEO. He replaces CEO Bill Lis, who retired Aug. 1. Interim Co-Presidents John Curnutte, the company’s head of R&D, and Mardi Dier, its...
23:58 , Apr 19, 2018 |  BC Innovations  |  Product R&D

Automation navigation

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
19:17 , Apr 13, 2018 |  BC Week In Review  |  Company News

CIRM launches industry partnership network for its stem cell projects

The California Institute for Regenerative Medicine (CIRM) launched its Industry Alliance Program (IAP) to secure industry partnerships and funding for its stem cell research projects. IAP will connect pharma, biotech and VC firms with CIRM-funded...